| Literature DB >> 29991502 |
Teresa Cejalvo1, Ana Judith Perisé-Barrios1, Isabel Del Portillo2, Eduardo Laborda3, Miguel A Rodriguez-Milla1, Isabel Cubillo1, Fernando Vázquez2, David Sardón2, Manuel Ramirez4, Ramon Alemany3, Noemí Del Castillo2, Javier García-Castro5.
Abstract
Dogs with spontaneous tumors treated in veterinary hospitals offer an excellent opportunity for studying immunotherapies, including oncolytic viruses. Oncolytic viruses have advanced into the clinic as an intratumorally administered therapeutic; however, intravenous delivery has been hindered by neutralization in the blood. To circumvent this hurdle, mesenchymal stem cells have been used as a "Trojan horse." Here, we present the treatment of 27 canine patients with cancer with canine mesenchymal stem cells infected with ICOCAV17, a canine oncolytic adenovirus. No significant adverse effects were found. The response rate was 74%, with 14.8% showing complete responses, including total remissions of lung metastasis. We detected virus infection, stromal degeneration, and immune cell infiltration in tumor biopsies after 4 weeks of treatment. The increased presence of antiadenoviral antibodies in the peripheral blood of treated dogs did not appear to prevent the clinical benefit of this therapy. These data indicate that oncolytic viruses loaded in mesenchymal stem cells represent an effective cancer immunotherapy.Significance: The classical clinical limitations of antitumoral viroimmunotherapy can be overcome by use of mesenchymal stem cells.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/17/4891/F1.large.jpg Cancer Res; 78(17); 4891-901. ©2018 AACR. ©2018 American Association for Cancer Research.Entities:
Mesh:
Year: 2018 PMID: 29991502 DOI: 10.1158/0008-5472.CAN-17-3754
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701